Compare Iris Energy Limited (IREN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iris Energy Limited vs Merck & Co., Inc. — how do they compare? Iris Energy Limited trades at $41.43 (market cap $14.37B), while Merck & Co., Inc. trades at $126 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 21.4× Iris Energy Limited's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals.
| IREN | MRK | |
|---|---|---|
Market Cap | $14.37B | $307.25B |
Sector | Energy | Health |
52-Week High | $76.41 | $129.52 |
52-Week Low | $15.40 | $77.60 |
Enterprise Value | $16.12B | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IREN trades at $40.20, up 19.57% in 24 hours but remains volatile amid a broader AI infrastructure stock sell-off. The stock shows a bearish technical signal with support at $31 and resistance at $36. Fundamentally, revenue grew to $501M in 2025 with a 20.88% net income margin, but recent quarters missed EPS expectations. The company is transitioning from Bitcoin mining to AI cloud services, with significant capital investment driving negative cash flow from investing activities.
Wall Street maintains a bullish stance with a $79.11 consensus price target and 71% buy ratings, citing IREN's AI infrastructure potential. However, execution risks, competitive pressures from Meta and peers, and recent earnings misses pose significant challenges. The stock's high valuation multiples (P/E 43.66) require flawless growth execution to justify current levels.
MRK trades at $126.33, down 0.92% on the day, with a neutral technical signal. The company reported strong 2025 results with revenue of $65.01B and net income of $18.25B, beating EPS estimates in recent quarters. Analyst consensus is bullish with a $137.30 price target, and recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is positive, supported by robust profitability and strategic acquisitions, though risks include rising debt levels and competitive pressures. The stock offers a dividend yield with a recent $0.85 payout, and institutional buying activity indicates confidence in long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
